CoChat

Vedolizumab in Inflammatory Bowel Disease Associated with Autoimmune Liver Disease Pre- and Postliver Transplantation: A Case Series

Open access
Lim, Tiong Yeng, Pavlidis, Polychronis, Gulati, Shraddha, Pirani, Tasneem, Samaan, Mark, Chung-Faye, Guy, Dubois, Patrick, Irving, Peter, Heneghan, Michael, Hayee, BuʼHussain · 2016 · Inflammatory Bowel Diseases
Cited by 27

The DOI matches its Crossref record.

Abstract

To the Editor: Inflammatory bowel disease (IBD) associated with primary and autoimmune sclerosing cholangitis seems to represent a distinct clinical entity in comparison with “classical” ulcerative colitis and Crohn's disease.1,2 Antitumor necrosis factor (TNF) therapy can be efficacious, but systemic complications remain a real concern, especially after liver transplantation (LT),3 whereas evidence for other therapeutic interventions is limited to preclinical models4 and small case series.5 Vedolizumab (VDZ), a humanized monoclonal antibody directed against the α4β7 integrin, is indicated for induction and maintenance of remission of moderate to severe IBD, either naive or refractory to anti-TNF agents. In this letter, we report our experience of VDZ for 10 patients with primary sclerosing cholangitis/autoimmune sclerosing cholangitis–IBD pre- and post-LT (n = 5, respectively). Table 1 summarizes the disease characteristics and outcomes. Patients' Clinical Characteristics Patients' Clinical Characteristics Overall, a clinical response was seen in 4/10 patients (40%), 1 of whom achieved clinical remission (sustained to last follow-up). Surgery was required for 1 patient during induction because of acute severe colitis. The median duration of VDZ therapy in the 9 patients who received maintenance was 7.4 (1.4–12.5) months. In responders, a drop in fecal calprotectin (μg/g; median 708 [60–2696] versus 90 [32–960], P = 0.03 by Wilcoxon test) and an improvement in quality of life scores were observed (5 [0, 13] versus 13 [8, 16], P = 0.03). Abnormalities in liver biochemistry were seen in 2 post-LT patients, but both had recurrence of their liver disease before VDZ initiation. No infective complications were attributed to VDZ use. There were no malignancies identified during the follow-up period. This is the first case series of VDZ use in primary sclerosing cholangitis/autoimmune sclerosing cholangitis–IBD patients pre- and post-LT. Therapy has been well tolerated by all patients, and no safety signals have been identified during the follow-up period despite concomitant immunosuppressants. Even in the context of anti-TNF failure, a good response rate has been documented with improvement in symptoms, objective markers of intestinal inflammation, and quality of life. Follow-up in this cohort is too short so far to comment on whether VDZ therapy influences the expected rate of pre-LT flares or post-LT recurrence of liver disease, but to date, no such events have been recorded. As experience increases, taking into account its potential beneficial effects for autoimmune liver disease and the infectious complications associated with anti-TNF use, it seems likely that VDZ will become the treatment of choice for IBD in this group of patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/mib.0000000000000906

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 27

Metadata

Authors
Lim, T. Y., Pavlidis, P., Gulati, S., Pirani, T., Samaan, M., Chung-Faye, G., Dubois, P., Irving, P., Heneghan, M., & Hayee, B.
Venue
Inflammatory Bowel Diseases
Published
2016-10
Volume
22
Issue
10
Pages
E39-E40
ISSN
1078-0998 (ISSN-L)
OpenAlex
W2517548808
Cited by
27
References
0
FWCI
3.67
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vedolizumab in Inflammatory Bowel Disease Associated with Autoimmune Liver Disease Pre- and Postliver Transplantation: A Case Series. https://app.cochat.ai/papers/10.1097/mib.0000000000000906
The paper
Lim, T. Y., Pavlidis, P., Gulati, S., Pirani, T., Samaan, M., Chung-Faye, G., Dubois, P., Irving, P., Heneghan, M., & Hayee, B. (2016). Vedolizumab in Inflammatory Bowel Disease Associated with Autoimmune Liver Disease Pre- and Postliver Transplantation: A Case Series. Inflammatory Bowel Diseases. https://doi.org/10.1097/mib.0000000000000906

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.